BOULDER, Colo., March 14 /PRNewswire/ -- Klearsen Corporation, a manufacturer of natural health care products, announced today that their KC- 287 antimicrobial compound was shown to be more effective against non- tuberculous M. avium and M. abscessus than any antibiotic presently in use to treat these conditions.
The testing, performed at a National Research Center, utilized an automated screening protocol to measure the inhibitory effect of various drugs on mycobacteria. "After having very good results against M. tuberculosis, it seemed like the obvious step to screen the compound against M. avium and M. abscessus," said Steve Frank, the project director. "We have been utilizing this compound in our patented Respiratory Inhalation Therapy treatment for years to deal with numerous ailments and this testing finally provides us with the substantiation necessary to move into the mycobacteria treatment arena."
Preliminary work with an MAC (Mycobacterium avium complex) patient in clinical trials has shown encouraging results and suggests that the treatment period for this condition could be reduced from a typical 12- to 16-month course of antibiotics to a 4-week course of the Klearsen Respiratory Inhalation Therapy. "This is a very exciting period of demonstration for our KC-287 antimicrobial compound," stated Chris Groutt, the Marketing Director. "We have all seen the dramatic capabilities of this product and now it is finally reaching the surface where it can benefit huge portions of the population."
The treatment utilizes a nebulized mist of KC-287 to repeatedly coat the inner surfaces of the lungs. Being on the air-side of the tissue and formulated to gain enhanced entry into the bacterial cells allow the active agent to very effectively kill the mycobacteria with very low total dose to the subject. Although the treatment is still in the experimental stage, early results are so encouraging, that clinical studies are moving forward.
Paul Whittle, the CEO of Klearsen Corp., is anxious to see this technology applied to MAC as well as tuberculosis patients: "Klearsen Corporation holds several patents relating to the respiratory therapy and the active agent. We are very pleased to see this level of performance in vivo."
Klearsen Corporation can be reached at 303-443-8700. Some of the technical reports can be accessed on-line at http://www.klearsen.com.
Contact: Chris Groutt, Klearsen Corporation, 1-888-303-3388, Chrisg@klearsen.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Klearsen CorporationCONTACT: Chris Groutt of Klearsen Corporation, +1-888-303-3388,Chrisg@klearsen.com
Web site: http://www.klearsen.com//